|Articles|May 7, 2023
- Pharmaceutical Executive: May 2023
- Volume 43
- Issue 5
Pharmaceutical Executive, May 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
From Science to Strategy | 2023 Emerging Pharma Leaderover 2 years ago
Committed to the Cause | 2023 Emerging Pharma Leaderover 2 years ago
A Knack for Problem-Solving | 2023 Emerging Pharma Leaderover 2 years ago
Mission-Fueled Mindset | 2023 Emerging Pharma Leaderover 2 years ago
Rejuvenating Lives | 2023 Emerging Pharma Leaderover 2 years ago
Optimized for Growth? Revenue Management in Pharmaover 2 years ago
Preparing for the End of the COVID Health Emergencyover 2 years ago
AI is a Tool, Not a Replacement for Employeesover 2 years ago
Ratings and Rankings: ESG Fundamentals for Pharma LeadersNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5

